Big Pharma At The Senate: When It Comes To Yes Or No Questions, There Are Still A Few Maybes
Executive Summary
Our question-by-question
You may also be interested in...
Mehta Analysis: BMS/Celgene Merger Shows Big Pharma Is Stuck In Wrong Groove
Bristol-Myers Squibb executives are justifying the acquisition of Celgene in terms that have been well-rehearsed through the history of big pharma mergers. But they are failing to consider radical changes to the environment in which pharma operates, argues Viren Mehta of Mehta Partners LLC.
Big Pharma Defuses Drug Pricing Landmines On Capitol Hill
Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.
REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'
Other sponsors could be using tactics other than REMS abuse to game the system, US FDA Commissioner Scott Gottlieb says.